Nazione: Singapore
Lingua: inglese
Fonte: HSA (Health Sciences Authority)
Erlotinib hydrochloride eqv Erlotinib
LOTUS INTERNATIONAL PTE. LTD.
L01EB02
TABLET, FILM COATED
Erlotinib hydrochloride eqv Erlotinib 150.00mg
ORAL
Prescription Only
Remedica Ltd
ACTIVE
2020-11-19
1 1. NAME OF THE MEDICINAL PRODUCT ALVOCEVA 25 mg tablets ALVOCEVA 50 mg tablets ALVOCEVA 100 mg tablets ALVOCEVA 150 mg tablets Not all presentations are available. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 25 mg erlotinib (as erlotinib hydrochloride). Each film-coated tablet contains 50 mg erlotinib (as erlotinib hydrochloride). Each film-coated tablet contains 100 mg erlotinib (as erlotinib hydrochloride). Each film-coated tablet contains 150 mg erlotinib (as erlotinib hydrochloride). Excipient with known effect: Each 25 mg film-coated tablet contains 23.98 mg lactose monohydrate. Each 50 mg film-coated tablet contains 47.97 mg lactose monohydrate. Each 100 mg film-coated tablet contains 95.93 mg lactose monohydrate. Each 150 mg film-coated tablet contains 143.90 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). White to yellowish, round biconvex, film-coated tablet, engraved with “25” on one side. The diameter of the tablet is 6.1 mm±5%. White to yellowish, round biconvex, film-coated tablet, engraved with “50” on one side. The diameter of the tablet is 7.6 mm±5%. White to yellowish, round biconvex, film-coated tablet, engraved with “100” on one side. The diameter of the tablet is 8.9 mm±5%. White to yellowish, round biconvex, film-coated tablet, engraved with “150” on one side. The diameter of the tablet is 10.5 mm±5%. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Non-Small Cell Lung Cancer (NSCLC): Erlotinib is indicated for the first-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations. Erlotinib is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy. Erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cance Leggi il documento completo
1 1. NAME OF THE MEDICINAL PRODUCT ALVOCEVA 25 mg tablets ALVOCEVA 50 mg tablets ALVOCEVA 100 mg tablets ALVOCEVA 150 mg tablets Not all presentations are available. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 25 mg erlotinib (as erlotinib hydrochloride). Each film-coated tablet contains 50 mg erlotinib (as erlotinib hydrochloride). Each film-coated tablet contains 100 mg erlotinib (as erlotinib hydrochloride). Each film-coated tablet contains 150 mg erlotinib (as erlotinib hydrochloride). Excipient with known effect: Each 25 mg film-coated tablet contains 23.98 mg lactose monohydrate. Each 50 mg film-coated tablet contains 47.97 mg lactose monohydrate. Each 100 mg film-coated tablet contains 95.93 mg lactose monohydrate. Each 150 mg film-coated tablet contains 143.90 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet (tablet). White to yellowish, round biconvex, film-coated tablet, engraved with “25” on one side. The diameter of the tablet is 6.1 mm±5%. White to yellowish, round biconvex, film-coated tablet, engraved with “50” on one side. The diameter of the tablet is 7.6 mm±5%. White to yellowish, round biconvex, film-coated tablet, engraved with “100” on one side. The diameter of the tablet is 8.9 mm±5%. White to yellowish, round biconvex, film-coated tablet, engraved with “150” on one side. The diameter of the tablet is 10.5 mm±5%. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Non-Small Cell Lung Cancer (NSCLC): Erlotinib is indicated for the first-line treatment of patients with locally advanced or metastatic non- small cell lung cancer (NSCLC) with EGFR activating mutations. Erlotinib is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy. Erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cance Leggi il documento completo